Led by Associate Professor of Hematology and Oncology Matthew Reilley, MD, the UVA Comprehensive Cancer Center (UVACCC) recently enrolled the first patient in a nationwide Phase 1 drug trial to evaluate a new immunotherapy drug’s potential to treat various forms of cancer. The study is expected to enlist more 200 patients over five years to … Continue reading UVA Cancer Center Enrolls First Patient in National Phase 1 Immunotherapy Trial